← All trials
NCT03997734
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2019
- Primary completion
- Oct 31, 2019
- Completion date
- Nov 30, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 34
- Arms / groups
- 5 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Frontier Biotechnologies Co., Ltd.Lead sponsor
- Frontier Biotechnologies Co., Ltd.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.